信州大学(Shinshu university)博士(医学)雑誌に発表。Int J Clin Oncol. [Epub ahead of print] (2013); doi:10.1007/s10147-013-0618-6.Thesis鈴木 尚徳. Efficacy and safety of advanced renal cell carcinoma patients treated with sorafenib: roles of cytokine pretreatment(進行性腎癌に対するソラフェニブの有効性および安全性:サイトカイン先行投与の効果). 信州大学, 2013, 博士論文.doctoral thesi
Background: Sunitinib and everolimus have been approved for first- and second-line treatment, respec...
Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment ...
Objective: Axitinib is a potent and selective second-generation inhibitor of vascular endothe-lial g...
AbstractBackgroundPatients with advanced renal cell carcinoma in routine clinical practice can diffe...
Objective: Effects of sorafenib in general clinical practice, especially those with patients of Asia...
Sorafenib has been recommended as first- or second-line treatment for metastatic renal cell carcinom...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
To evaluate the efficacy and safety of sorafenib for Korean patients with metastatic renal cell carc...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
To evaluate the efficacy and safety of sorafenib for Korean patients with metastatic renal cell carc...
Objective: Effects of sorafenib in general clinical practice, especially those with patients of Asia...
<div><p>Background</p><p>Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (R...
Objective To evaluate the efficacy and safety of sorafenib for Korean patients with metastatic renal...
We conducted this largest, single-center, retrospective study to determine the efficacy of sorafenib...
目的 评价索拉非尼治疗晚期肾癌患者的疗效及安全性.方法 回顾性分析自2007年1月至2013年8月于北京大学第一医院泌尿外科诊治的74例接受索拉非尼治疗的晚期肾癌患者.男性53例,女性21例,中位年龄...
Background: Sunitinib and everolimus have been approved for first- and second-line treatment, respec...
Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment ...
Objective: Axitinib is a potent and selective second-generation inhibitor of vascular endothe-lial g...
AbstractBackgroundPatients with advanced renal cell carcinoma in routine clinical practice can diffe...
Objective: Effects of sorafenib in general clinical practice, especially those with patients of Asia...
Sorafenib has been recommended as first- or second-line treatment for metastatic renal cell carcinom...
Renal cell carcinoma is a kidney cancer that originates in the lining of the proximal convoluted t...
To evaluate the efficacy and safety of sorafenib for Korean patients with metastatic renal cell carc...
Ding-Wei Ye, Hai-Liang Zhang 1Department of Urology, Fudan University Shanghai Cancer Center, 2Depar...
To evaluate the efficacy and safety of sorafenib for Korean patients with metastatic renal cell carc...
Objective: Effects of sorafenib in general clinical practice, especially those with patients of Asia...
<div><p>Background</p><p>Sorafenib was FDA approved in 2005 for treatment of renal cell carcinoma (R...
Objective To evaluate the efficacy and safety of sorafenib for Korean patients with metastatic renal...
We conducted this largest, single-center, retrospective study to determine the efficacy of sorafenib...
目的 评价索拉非尼治疗晚期肾癌患者的疗效及安全性.方法 回顾性分析自2007年1月至2013年8月于北京大学第一医院泌尿外科诊治的74例接受索拉非尼治疗的晚期肾癌患者.男性53例,女性21例,中位年龄...
Background: Sunitinib and everolimus have been approved for first- and second-line treatment, respec...
Purpose: The present study compared the efficacy of sunitinib and sorafenib as first-line treatment ...
Objective: Axitinib is a potent and selective second-generation inhibitor of vascular endothe-lial g...